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From June 1997 to December 2001, results of in vitro susceptibility tests of yeast isolates from 35 countries
were collected. For 2001 alone, fluconazole results were reported for 22,111 yeast isolates from 77 institutions
in 30 countries. Of these isolates, 18,569 were also tested for susceptibility to voriconazole. All study sites tested
clinical yeast isolates by recently endorsed NCCLS disk diffusion method M44-P. Disk test plates were
automatically read and results were recorded with the BIOMIC Image Analysis System. Species, drug, zone
diameter, susceptibility category, MIC, and quality control results were electronically submitted by e-mail
quarterly for analysis. Duplicate test results (same patient and same species with same sensitivity-resistance
profile and biotype results during any 7-day period) and uncontrolled test results were eliminated from this
analysis. The proportion of Candida albicans isolates decreased from 69.7% in 1997 to 1998 to 63.0% in 2001,
and this decrease was accompanied by a concomitant increase in C. tropicalis and C. parapsilosis. The suscep-
tibility (susceptible [S]or susceptible-dose dependent [S-DD]) of C. albicans isolates to fluconazole was
virtually unchanged, from 99.2% in 1997 to 99% in 2001; the C. glabrata response to fluconazole was unchanged,
from 81.5% S or S-DD in 1997 to 81.7% in 2001, although the percentage of resistant isolates from blood and
upper respiratory tract samples appeared to increase over the study period; the percentage of S C. parapsilosis
isolates decreased slightly, from 98% S or S-DD in 1997 to 96% in 2001; and the percentage of S isolates of C.
tropicalis increased slightly, from 95.7% in 1997 to 96.9% in 2001. The highest rate of resistance to fluconazole
among C. albicans isolates was noted in Ecuador (7.6%, n  250). Results from this investigation indicate that
the susceptibility of yeast isolates to fluconazole has changed minimally worldwide over the 4.5-year study
period and that voriconazole demonstrated 10- to 100-fold greater in vitro activity than fluconazole against
most yeast species.
Systemic yeast infections are a common consequence of
immunosuppression, long-term indwelling catheters, and en-
docrinopathies. Subcutaneous, cutaneous, and superficial yeast
infections also occur in both immunosuppressed and immuno-
competent populations. Fluconazole is commonly used for se-
rious mucocutaneous and systemic disease, as well as for post-
surgical and posttransplant prophylaxis. Given the widespread
use of this agent, concerns about the development of resistance
in yeast have been raised (11, 17, 22).
Recently, a new extended-spectrum triazole, voriconazole
(Vfend; Pfizer), has been approved by the U.S. Food and Drug
Administration (FDA) for first-line treatment of invasive as-
pergillosis and for treatment of patients refractory to other
therapies for serious infections caused by Scedosporium apio-
spermum and Fusarium spp. In Europe, voriconazole has been
approved for treatment of invasive aspergillosis, treatment of
fluconazole-resistant serious invasive Candida (including Can-
dida krusei) infections, and treatment of serious fungal infec-
tions by Scedosporium spp. and Fusarium spp. A major advan-
tage of voriconazole over other recently approved antifungal
agents used to treat systemic disease is that it can be admin-
istered orally after initial intravenous loading and administra-
tion of maintenance doses. While voriconazole does not yet
have an FDA-approved indication for the treatment of Can-
dida infections, phase III clinical trials are ongoing and vori-
conazole has shown enhanced activity against various yeast
species in vitro (3, 10, 19).
Breakpoints (susceptible [S], susceptible-dose dependent
[S-DD], and resistant [R]) for fluconazole have been estab-
lished (20), making in vitro susceptibility test results useful to
help guide antifungal therapy. Breakpoints for voriconazole
have not yet been established. Pharmacokinetically, flucon-
azole differs from voriconazole in that its concentration in
serum is dependent on the dose administered; i.e., a higher
dose of fluconazole leads to a higher concentration in serum
(and hence the use of the S-DD designation) (6). The ap-
proved dosing regimen for voriconazole is two loading doses of
6 mg/kg given intravenously 12 h apart, followed by 4 mg/kg (or
3 mg/kg if tolerance is a problem) every 12 h as a maintenance
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dose (5). Patients (40 kg) may be switched at any time to oral
therapy with 200 mg every 12 h or an increase to 300 mg every
12 h if an inadequate response is evident. The adult dosing
regimen should yield a Cmax in plasma of approximately 2 to 5
g/ml.
In the present study, entitled the ARTEMIS DISK Surveil-
lance Study, we evaluated global trends in the susceptibility of
yeasts to fluconazole over a 4.5-year period by using the
NCCLS M44-P disk diffusion method, in which zone sizes have
been correlated with established breakpoints. We also evalu-
ated yeast susceptibility to voriconazole by this disk method.
The disk method was used because it provides a low-cost,
reproducible, and accurate susceptibility test that can easily be
adapted in hospital laboratories worldwide. This method
should help to guide clinical therapy, provide epidemiology
data, and reduce the number of misleading reports of drug
resistance based on biased selective testing. We report the
results of this global survey and a comparison of the activities
of fluconazole and voriconazole against a large number of
clinical isolates and a broad range of yeast species.
MATERIALS AND METHODS
Test sites. Eighty-nine sites in 35 countries contributed some data during the
4.5-year study period (June 1997 to December 2001), and 77 sites in 30 countries
contributed data in 2001. All yeasts considered pathogens from all body sites and
isolated from patients in all in-hospital locations during the study period were
tested. Yeasts considered by the investigator to be colonizers, that is, not exhib-
iting pathology, were excluded. Identification of isolates was performed in ac-
cordance with each site’s routine methods.
Susceptibility test method. The NCCLS M44-P method is similar to the
NCCLS M2-A6 disk test method for bacteria (13), except that Mueller-Hinton
agar is supplemented with 2% glucose (to support growth) and 0.5 g of meth-
ylene blue (improves zone edge definition) per ml. Mueller-Hinton agar medium
was obtained locally at all sites. The inoculum was adjusted to match a 0.5
McFarland density standard. Plates were incubated for 18 to 24 h at 35 to 37°C.
Slowly growing isolates, primarily members of the genus Cryptococcus, were read
after 48 h of incubation. The method used in this study varied from NCCLS
M44-P only in incubation time; 18 to 24 h versus 20 to 24 h in M44-P.
Pfizer Inc. supplied study sites with 25-g fluconazole disks, 1-g voriconazole
disks (manufactured by Becton Dickinson, Sparks, Md.), quality control (QC)
strain C. albicans ATCC 90028 (recommended acceptable-performance range of
28 to 39 mm for fluconazole and 31 to 42 mm for voriconazole), and an optional
QC strain, C. parapsilosis ATCC 22019 (reference range of 22 to 33 mm for
fluconazole and 28 to 37 mm for voriconazole).
Interpretive breakpoints for fluconazole disk diffusion testing (12) were based
on zones correlated with NCCLS-recommended category breakpoints for the
reference broth dilution method (14). In January 2003, the NCCLS Antifungal
Susceptibility Subcommittee issued formal fluconazole disk interpretive criteria,
as well as QC ranges for reference strains, for both fluconazole and voriconazole.
The fluconazole MIC breakpoints are as follows: S, 8 g/ml; S-DD, 16 to 32
g/ml; R,64 g/ml. The corresponding zone interpretive criteria are as follows:
S, 19 mm; S-DD, 15 to 18 mm; R, 14 mm. MICs reported in this study were
automatically calculated by the BIOMIC System software (Giles Scientific Inc.,
Santa Barbara, Calif.; www.biomic.com). The BIOMIC MICs are determined by
a method that is basically the same as the Etest. The continuous agar disk
gradient is calibrated against NCCLS reference broth method MIC results on a
group of isolates and then that “scale” (disk or Etest zone versus MIC in
BIOMIC software or printed on the Etest) is used to “look up the MIC.” The
regression data used by the BIOMIC software were provided to NCCLS during
review of the yeast disk method and interpretive-QC guidelines (A. Barry and S.
Brown, data on file). Other investigators have shown that zone sizes correlate
well with broth dilution MICs and that the BIOMIC-interpreted MICs are as
reliable as those obtained by Etest (16, 17). QC tests were required to be
acceptable within 7 days of testing.
Data analysis. All yeast disk test results were read by electronic image analysis
and interpreted and recorded by a BIOMIC Plate Reader System (Giles Scien-
tific Inc.). Test results were sent by e-mail to Giles Scientific for analysis. Zone
diameter, susceptibility category (S, S-DD, or R), MIC, and QC test results were
recorded electronically. Patient and doctor names, duplicate test results (same
patient-same species-same biotype results), and uncontrolled results were auto-
matically eliminated prior to analysis.
RESULTS
Isolation rates by species. In each year of the study, the most
commonly isolated yeast was C. albicans (Table 1). A decreas-
ing trend in the rate of C. albicans isolation (6.74%) was
evident over the 4.5-year period, along with increasing rates of
isolation of C. tropicalis, C. glabrata, C. parapsilosis, and C.
rugosa totaling 7.1%. Unusual yeasts, such as C. pelliculosa,
Pichia species, and C. zeylanoides, were reported during the
last 2 years of the study but contributed only 1.12% of the total
year 2001 isolates. Unidentified (“other”) yeasts represented
0.51 to 3.07% of the total number of isolates; this percentage
tended to decrease during the last 2 years, as more isolates
were apparently identified to the species level. The species
most commonly isolated from blood specimens were, in de-
scending order, C. albicans, C. parapsilosis, C. tropicalis, C.
glabrata, and C. guilliermondii, and those from intensive care
units (ICUs) were C. albicans, C. glabrata, C. tropicalis, C.
parapsilosis and C. krusei.
Fluconazole susceptibility by species. C. parapsilosis was the
only species with 20 or more isolates that exhibited a consistent
decrease in fluconazole susceptibility over the 4.5-year study
period (Table 2), with a relatively small decrease from 98.0 to
96.0%. During this same period, the rate of isolation of C.
parapsilosis increased from 4.04 to 6.41% of the total number
of isolates. Year-to-year fluconazole susceptibility rate vari-
ability was expected over the study period and was evident for
some species, including C. glabrata, C. krusei, and C. lusitaniae.
The percentage of S strains of C. tropicalis appeared to in-
crease, although minimally, during the 4.5-year period, from
95.7 to 96.9%; during this same period, the rate of isolation
increased from 4.38 to 7.19% of the total. The fluconazole
resistance trends of six yeast species during the study period
are shown graphically in Fig. 1.
C. albicans susceptibility by country, patient location, and
specimen type. In countries with at least 20 C. albicans isolates
each year, no increase in relative resistance was evident (Table
3). The proportion of fluconazole-susceptible C. albicans iso-
lates appeared to decrease, although only minimally, over the
4.5 years in hospital general medicine units (from 99.7 to
98.8%) and medical ICUs (from 99.6 to 99.0%) (Table 4).
Resistant yeast isolates were most often associated with spec-
imens from the respiratory tract and miscellaneous or other
sites and less often seen in blood, genital tract, and biliary tract
samples (Table 5). Respiratory and unspecified sites were the
most common specimen types from which C. albicans was
isolated. The percentage of resistant isolates from respiratory
tract specimens was not disproportionate (i.e., not more than
twofold higher) compared to that of resistant isolates from all
sites (data not shown). Within the general medicine unit loca-
tions, 31.4% of all resistant isolates were obtained from mis-
cellaneous or other specimens. When examined for overall
rates of fluconazole-susceptible C. albicans by location of the
source patient in the hospital, the neonatal ICU (NICU) was
the only location that showed a disproportionately lower sus-
ceptibility rate in 2000 (95.9%) and 2001 (97.1%), relative to
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the 100% susceptibility reported in 1997 to 1999 (Table 4). No
one specimen type appeared more likely than others to yield
resistant yeast isolates in 2001 (Table 5).
Distribution of fluconazole-susceptible C. albicans in genital
isolates by country. Fluconazole and other azoles are com-
monly used for the treatment of genital candidiasis, which is
most frequently caused by C. albicans (23). Diminished sus-
ceptibility is therefore likely to be recognized first in genital
source isolates. In countries from which 4.5-year data were
available, there was no obvious trend toward reduced flucon-
azole susceptibility of C. albicans isolates (Table 6). Suscepti-
bility rates in 2001 were generally high (99%), but several
countries (although with low total numbers of isolates tested),
including Ecuador, Argentina, and Hungary, had minimally
lower rates.
Yearly change in fluconazole-resistant C. glabrata by patient
location and specimen type. As noted above, the overall resis-
tance of C. glabrata did not show a steady increase but fluctu-
ated. No specific patient location with more than 20 isolates
per year showed a steady increase in the percentage of flucon-
azole-resistant C. glabrata (Table 7). Two locations, obstetrics-
gynecology (ObGyn) units and surgical ICUs, however, each
had at least a twofold increase in resistant C. glabrata in 2001
compared to all other years. Additional surveillance years are
needed to see if these increases will be maintained. Only two
specimen types for which more than 20 isolates were available
per year, bloodstream and upper respiratory tract specimens,
were associated with increases in the percentage of flucon-
azole-resistant C. glabrata isolates for the last 2 years of the
study versus the first 2.5 years (Table 8).
Voriconazole versus fluconazole disk QC in 2001. C. albicans
ATCC 90028 and C. parapsilosis ATCC 22019 were used as QC
strains for fluconazole and voriconazole disk testing. 2001 was
the first year for inclusion of voriconazole and thus the first for
which the reliability of QC isolates with voriconazole was as
good as that established for fluconazole. More than 90% of all
QC tests for C. albicans ATCC 90028 fell within the accept-
able-performance ranges for fluconazole (90%) and voricon-
azole (95%) and yielded normal distributions. Fluconazole QC
test results obtained with C. parapsilosis ATCC 22019 were not
as tightly clustered as those obtained with C. albicans ATCC
90028, with only 82% of the tests within the acceptable-per-
formance range. Only 72% of the voriconazole QC test results
with C. parapsilosis ATCC 22019 were within the acceptable
QC performance range (28 to 37 mm), primarily because of the
number of zone readings of 38 mm. Although QC readings
showed a bell-shaped distribution, this was not within the QC
performance range recommended by the study involving eight
expert laboratories presented to the NCCLS (S. Brown et al.,
2002 data on file). Out-of-range QC test results obtained with
C. parapsilosis were more likely to be above the range for both
fluconazole and voriconazole (Fig. 2).
MIC50 and MIC90 ranges for fluconazole and voriconazole.
Among all of the species of which 20 or more isolates were
TABLE 1. 4.5-year comparison of isolation rates by organisma
Organism(s)
1997–1998 data 1999 data 2000 data 2001 data
% of
total n
% of
total n
% of
total n
% of
total n
Candida albicans 69.74 16,473 66.86 14,648 66.00 7,936 63.00 13,930
Candida glabrata 10.47 2,474 9.33 2,045 9.27 1,115 10.76 2,379
Candida tropicalis 4.38 1,035 5.09 1,114 7.01 843 7.19 1,590
Candida parapsilosis 4.04 955 4.69 1,028 5.40 649 6.41 1,418
Candida species 3.76 889 5.74 1,257 3.63 437 3.24 717
Candida krusei 1.57 372 2.09 457 3.14 377 2.41 533
Cryptococcus neoformans 1.16 275 1.52 334 0.66 79 1.40 310
Other yeasts 3.07 725 1.73 379 0.51 61 1.14 258
Candida guilliermondii 0.47 111 0.77 168 0.72 86 0.74 163
Candida rugosa 0.03 7 0.03 7 0.17 21 0.67 149
Candida lusitaniae 0.49 115 0.45 99 0.52 62 0.55 121
Trichosporon sp. 0.29 68 0.35 77 0.57 69 0.47 104
Saccharomyces cerevisiae 0.48 58 0.40 89
Candida kefyr 0.14 34 0.38 83 0.53 64 0.39 86
Candida famata 0.08 19 0.22 49 0.43 52 0.24 53
Candida norvegensis 0.00 1 0.07 9 0.14 31
Trichosporon beigelii/cutaneum 0.21 26 0.14 30
Candida inconspicua 0.07 9 0.13 28
Candida zeylanoides 0.03 4 0.09 19
Blastoschizomyces capitatus 0.01 1 0.08 17
Candida dubliniensis 0.01 1 0.08 17
Rhodotorula sp. 0.14 33 0.14 31 0.14 17 0.07 16
Candida lipolytica 0.06 7 0.06 14
Candida pelliculosa 0.01 1 0.06 14
Cryptococcus laurentii 0.01 1 0.06 13
Saccharomyces sp. 0.15 36 0.59 130 0.19 23 0.05 10
Pichia sp. 0.06 7 0.02 5
Hansenula anomala 0.08 10 0.01 2
Total 23,621 21,907 12,025 22,111
a All specimen types were tested, all locations were in hospitals, and 89 institutions participated.
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tested in 2001, only C. krusei and C. inconspicua exhibited
MIC50s (MICs for 50% of the isolates tested) greater than the
R breakpoint of 64 g/ml for fluconazole. The fluconazole
MIC50s and MIC90s for C. albicans were within the S break-
point of 8 g/ml. For C. glabrata isolates (n  2,379), the
fluconazole MIC50 of 10.6 g/ml is in the S-DD category, while
the MIC90 was 165 g/ml, well above the R breakpoint.
No country had C. albicans isolates with fluconazole MIC50s
TABLE 2. 4.5-year comparison of fluconazole resistance by organisma
Organism(s)
1997–1998 data 1999 data 2000 data 2001 data
% R n % R n % R n % R n
Candida albicans 0.8 16,473 0.8 14,648 1.5 7,936 1.0 13,930
Candida glabrata 18.5 2,474 22.8 2,045 14.4 1,115 18.3 2,379
Candida tropicalis 4.3 1,035 3.3 1,114 3.1 843 3.1 1,590
Candida parapsilosis 2.0 955 2.8 1,028 2.9 649 4.0 1,418
Candida species 15.6 889 7.1 1,257 10.1 437 9.6 717
Candida krusei 56.5 372 71.3 457 68.2 377 70.2 533
Cryptococcus neoformans 11.3 275 3.6 334 8.9 79 14.5 310
Other yeasts 15.4 725 18.5 379 23.0 61 9.5 253
Candida guilliermondii 6.3 111 9.5 168 26.7 86 11.7 163
Candida rugosa 28.6 7 14.3 7 42.9 21 29.5 149
Candida lusitaniae 2.6 115 4.0 99 1.6 62 6.6 121
Trichosporon sp. 2.9 68 6.5 77 5.8 69 4.8 104
Saccharomyces cerevisiae 5.2 58 10.1 89
Candida kefyr 0.0 34 4.8 83 3.1 64 2.3 86
Candida famata 47.4 19 10.2 49 13.5 52 15.1 53
Candida norvegensis 0.0 1 55.6 9 45.2 31
Trichosporon beigelii/cutaneum 38.5 26 26.7 30
Candida inconspicua 55.6 9 57.1 28
Candida zeylanoides 0.0 4 52.6 19
Blastoschizomyces capitatus 0.0 1 11.8 17
Candida dubliniensis 0.0 1 0.0 17
Rhodotorula sp. 90.9 33 90.3 31 94.1 17 93.8 16
Candida lipolytica 0.0 7 28.6 14
Candida pelliculosa 0.0 1 0.0 14
Cryptococcus laurentii 0.0 1 7.7 13
Saccharomyces sp. 0.0 36 3.1 130 4.3 28 0.0 10
Pichia sp. 14.3 7 0.0 5
Hansenula anomala 0.0 10 0.0 2
Total 23,621 21,907 12,025 22,111
a All specimen types were tested, all locations were in hospitals, 89 and institutions participated. N is the total count for that period and organism.
FIG. 1. Percentage of fluconazole-resistant isolates of the six species most commonly isolated during the 4.5-year study period. With the
exception of the year 2000 for C. neoformans, at least 100 isolates of each species were tested in each year.
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higher than the S breakpoint, but five countries (Australia,
Colombia, Ecuador, Hungary, and Russia) had populations
with MIC90s of greater than 8 g/ml (Table 9). The MIC90s for
Australia and Russia, however, were based on only 21 and 11
isolates, respectively, and may represent sample bias.
In comparison to those of fluconazole, voriconazole MIC50s
for C. albicans were universally less than 0.1 g/ml (Table 9).
Ecuador had the highest voriconazole MIC50 for C. albicans
(0.096 g/ml) (Table 9). Similarly, the highest fluconazole
MICs for C. albicans were noted in Ecuador, suggesting cross-
TABLE 3. 4.5-year comparison of fluconazole-resistant C. albicans by countrya
Country (no. of sites)
1997–1998 data 1999 data 2000 data 2001 data
% R n % R n % R n % R n
Argentina (3) 1.1 183 2.3 172 1.4 74 1.6 607
Australia (2) 17.6 102 5.9 101 9.5 21
Belgium (3) 0.1 824 0.5 566 0.3 300 0.0 450
Brazil (2) 0.0 44 1.4 517 5.3 475 0.0 446
Canada (2) 0.0 87
China (2) 2.3 86 9.8 41 1.8 113 2.2 93
Colombia (2) 1.9 52 1.0 102 1.8 390
Czech Republic (2) 1.0 308 0.5 836 0.5 985 0.2 938
Ecuador (1) 3.8 52 11.0 210 7.6 250
France (4) 1.2 86 1.2 170 2.5 204 0.9 456
Germany (6) 5.0 80 1.0 102 0.0 19 0.3 299
Greece (1) 9.0 67 2.8 109 3.6 138 2.3 88
Hungary (5) 2.3 521 2.2 501 1.8 1,016
Italy (7) 1.9 1,009 1.1 696
Japan (1) 0.0 4
Malaysia (1) 0.0 424 0.0 295 0.0 619 0.2 1,246
Mexico (2) 0.0 20 0.0 46 0.0 17 0.0 23
The Netherlands (1) 1.1 2,097 0.4 1,790 1.5 1,204
Peru (1) 0.7 550
Poland (1) 0.0 172 0.0 53 0.0 47 0.0 170
Portugal (1) 15.1 126 8.9 90
Russia (1) 0.0 21 0.0 21 9.1 11
Singapore (1) 0.5 200
Slovakia (4) 0.0 349 0.0 189 0.0 138 0.5 391
South Africa (6) 0.4 2,596 0.1 2,893 0.3 1,249 0.6 1,049
South Korea (1) 0.0 439 0.7 139 0.0 426
Spain (2) 1.5 1,106 1.9 736 0.4 774 0.9 969
Sweden (1) 1.1 358 1.4 71
Switzerland (2) 3.1 130 1.2 161
Taiwan (3) 0.0 114 0.0 5 0.0 399
Thailand (2) 0.0 34 0.0 80 0.0 19 0.8 130
Turkey (2) 3.0 67 0.0 2 1.1 89 1.4 141
United Kingdom (4) 0.2 6,406 0.7 4,422 0.4 759 0.1 977
United States (9) 2.1 676
Venezuela (1) 16.7 30 3.7 27 9.5 95 1.7 120
Total 0.8 16,473 0.8 14,648 1.5 7,936 1.0 13,930
a All specimen types were tested, all locations were in hospitals, and 89 institutions participated. n is total count for that period and country.
TABLE 4. 4.5-year comparison of fluconazole-resistant C. albicans by locationa
Location (unit)
1997–1998 data 1999 data 2000 data 2001 data
% R n % R n % R n % R n
Dermatology 0.0 68 2.2 139 0.9 113 1.2 253
Hematology-oncology 1.3 397 0.9 939 2.0 395 0.8 1,063
Medical 0.3 1,040 0.3 1,797 0.8 2,369 1.2 2,818
Medical ICU 0.4 494 0.6 1,263 1.0 525 1.0 1,159
NICU 0.0 62 0.0 72 4.1 73 2.9 140
ObGyn 1.4 699 0.9 1,069 0.3 793 0.7 1,589
Other 0.9 12,505 1.3 5,873 2.5 2,515 1.0 4,597
Outpatient 0.8 473 0.5 1,470 2.1 606 0.9 1,004
Surgical 1.3 239 0.0 368 1.0 299 0.9 861
Surgical ICU 0.0 116 0.0 247 0.5 194 0.0 342
Urology 0.0 380 0.1 1,411 0.0 54 1.0 104
Total 0.8 16,473 0.8 14,648 1.5 7,936 1.0 13,930
a All specimen types were tested, and 89 institutions participated. n is the total count for that period and location.
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resistance. However, the voriconazole MIC50 of 0.096 g/ml is
well within the range of voriconazole concentrations pharma-
cologically achievable in plasma. However, the fluconazole and
voriconazole data from Ecuador were from only one hospital.
The highest voriconazole MIC90 for C. albicans isolates was 1.5
g/ml from both Hungary and Mexico. The species with the
highest voriconazole MIC50s were C. krusei (1.5 g/ml) and
Trichosporon beigelii (1.5 g/ml), followed by C. inconspicua
(0.63 g/ml) and C. glabrata (0.63 g/ml). Elevated MIC50s
and MIC90s did not appear to be associated with any specimen
type or hospital location (data not shown).
Comparison of fluconazole and voriconazole activities. Rel-
ative to fluconazole, voriconazole demonstrated about 1 to 2
logs greater potency against all of the yeast species combined
(Fig. 3), and this observation was consistent for all of the
species tested. The greater potency of voriconazole was dem-
onstrated against all species, and five species, C. krusei, Cryp-
tococcus neoformans, C. rugosa, C. norvegensis, and C. incon-
spicua, demonstrated markedly greater susceptibility to
voriconazole than to fluconazole.
DISCUSSION
A simple, automated disk diffusion test plate reader system,
the BIOMIC, was used to facilitate consistent, accurate read-
ing, interpretation, and recording of QC and isolate test re-
TABLE 5. 4.5-year comparison of fluconazole-resistant C. albicans
by specimen typea
Specimen type
1997–1998
data 1999 data 2000 data 2001 data
% R n % R n % R n % R n
Biliary tract 0.0 74 0.0 24 0.0 6 0.0 35
Blood 0.0 480 1.3 399 1.9 270 0.5 836
CSFb 0.0 12 0.0 12 0.0 5 0.0 39
Genital 0.5 610 0.4 984 0.8 2,208 0.6 3,382
Lower G.I.c tract 0.2 1,088 1.7 709 2.6 232 1.8 379
Lower respiratory tract 0.7 3,170 0.9 2,772 0.9 1,892 1.1 2,564
Miscellaneous/other 1.1 6,870 0.6 5,985 3.4 1,062 1.2 2,307
Miscellaneous/fluids 1.3 238 1.6 251 1.0 101 0.8 368
Skin/soft tissue 0.6 505 0.2 412 2.7 376 1.1 718
Upper respiratory tract 1.3 1,628 1.9 1,710 1.4 1,024 1.5 1,870
Urinary tract 0.6 1,803 0.3 1,390 1.4 760 0.8 1,432
Total 0.8 16,473 0.8 14,648 1.5 7,936 1.0 13,930
a All locations were in hospitals and 89 institutions participated. n is the total
count for that period and specimen type.
b CSF, cerebrospinal fluid.
c G.I., gastrointestinal.
TABLE 6. 4.5-year comparison, by country, of fluconazole-resistant
genital isolates of C. albicansa
Country
1997–1998
data 1999 data 2000 data 2001 data
% R n % R n % R n % R n
Argentina 20.0 5 6.3 16 2.5 80
Australia 0.0 2
Belgium 0.0 8 0.0 15 1.4 74 0.0 157
Brazil 0.0 3 0.0 74
China 0.0 6 0.0 13
Colombia 0.0 4 0.0 7 0.0 28
Czech Republic 0.0 6 1.3 152 0.4 240 0.0 130
Ecuador 0.0 6 33.3 21 5.1 39
France 0.0 1 0.0 1 1.7 116 0.0 60
Germany 0.0 1 0.0 6 0.0 1 0.0 68
Greece 0.0 31 0.0 26 0.0 12
Hungary 0.0 81 0.0 78 2.8 360
Italy 1.3 306 0.0 181
Malaysia 0.0 4 0.0 142 0.0 434 0.0 785
Mexico 0.0 1
The Netherlands 0.0 78 0.9 113
Poland 0.0 15 0.0 4 0.0 4
Russia 0.0 11 0.0 5
Singapore 0.0 30
Slovakia 0.0 2 0.0 35
South Africa 0.5 189 0.0 243 0.0 43 0.0 153
South Korea 0.0 14 0.0 6 0.0 7
Spain 1.2 163 0.8 121 0.3 294 0.8 367
Sweden 0.0 4
Switzerland 0.0 4 0.0 8
Taiwan 0.0 3
Turkey 0.0 1
United Kingdom 0.0 171 0.0 81 0.2 534 0.2 622
United States 0.0 25
Venezuela 0.0 3 0.0 52
Total 610 984 2,208 3,382
a Genital isolates only were tested, all locations were in hospitals, and 89
institutions participated. n is the total count for that period and country.
TABLE 7. 4.5-year comparison of fluconazole-resistant C. glabrata
by locationa
Location (unit)
1997–1998
data 1999 data 2000 data 2001 data
% R n % R n % R n % R n
Dermatology 0.0 2 0.0 8 10.0 10 4.8 21
Hematology-oncology 4.9 103 16.7 192 20.6 63 16.8 190
Medical 41.4 186 30.2 324 14.8 257 18.2 461
Medical ICU 31.5 111 24.9 217 15.4 91 14.0 228
NICU 90.9 11 50.0 22 28.6 7 45.8 48
ObGyn 7.3 137 8.6 187 7.6 118 38.9 208
Other 16.6 1,768 21.4 754 15.1 358 13.7 819
Outpatient 16.3 49 32.9 155 14.6 128 14.5 131
Surgical 14.8 54 16.2 74 17.1 35 16.5 170
Surgical ICU 18.5 27 13.3 45 12.2 41 25.9 85
Urology 23.1 26 37.3 67 8.3 12 16.7 18
Total 2,474 2,045 1,115 2,379
a All specimen types were tested, and 89 institutions participated. n is the total
count for that period and location.
TABLE 8. 4.5-year comparison of fluconazole-resistant C. glabrata
by specimen type
Specimen type
1997–1998
data 1999 data 2000 data 2001 data
% R n % R n % R n % R n
Billary tract 0.0 16 0.0 5 38.5 13
Blood 13.1 168 15.8 95 22.9 70 17.8 259
CSFb 100.0 1 0.0 3 100.0 1 0.0 1
Genital 10.9 110 9.0 188 10.6 311 30.7 437
Lower G.I.c tract 8.4 154 10.3 97 10.5 57 12.2 98
Lower respiratory tract 25.3 297 29.6 321 18.2 159 20.8 274
Miscellaneous/other 18.1 812 25.3 671 15.3 98 14.0 386
Miscellaneous fluids 10.2 59 20.0 35 23.5 17 15.3 85
Skin/soft tissue 20.5 73 23.2 69 23.5 34 13.6 108
Upper respiratory tract 10.3 195 11.8 169 12.7 118 17.3 248
Urinary tract 25.0 589 29.6 392 13.6 250 12.2 475
Total 2,474 2,045 1,115 2,379
aAll locations were in hospitals, and 89 institutions participated. n is the total
count for that period and specimen type.
b CSF, cerebrospinal fluid.
c G.I., gastrointestinal.
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sults. Quantitative quality-controlled test results were assessed
for trends in fluconazole susceptibility over a 4.5-year period in
35 countries. In this study, QC isolates alone were used to
validate the data. While this approach is not as definitive as
outside test validation, our data appear to be similar to those
obtained by others who conducted less geographically and tem-
porally broad studies (2, 19, 21). In the present study, C. albi-
cans was the yeast most commonly isolated from patient spec-
imens. Despite the widespread use of fluconazole for more
than a decade, there was no evidence that C. albicans has
FIG. 2. Distribution of zone sizes obtained with the QC isolates of C. albicans ATCC 90028 (A and B) and C. parapsilosis ATCC 22019 (C and
D) tested against fluconazole (A and C) and voriconazole (B and D). The reference acceptable-performance ranges for fluconazole and
voriconazole are 28 to 39 and 31 to 452 mm, respectively, when tested with C. albicans and 22 to 33 and 28 to 37 mm, respectively, when tested
with C. parapsilosis. C. parapsilosis was more often than C. albicans not with the QC limits of both antifungal agents. C. albicans was generally with
the limits (90% for fluconazole and 95% for voriconazole).
FIG. 3. Cumulative susceptibility of yeast isolates to fluconazole and voriconazole based on all of the organisms tested in the year 2001 (22,111
isolates for fluconazole and 18,569 isolates for voriconazole).
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developed increased resistance to fluconazole over the 4.5-year
study period. C. glabrata, which exhibits less susceptibility to
fluconazole and is considered an emerging pathogen (4, 7),
also did not exhibit increased resistance with time. Only C.
parapsilosis exhibited a consistent trend of decreased flucon-
azole susceptibility over the study period, from 98 to 96% S.
Given that the isolation rate of C. parapsilosis increased from
4.0 to 6.4% of the total number of yeast isolates collected
during the study period, that this species is commonly isolated
from NICU patients, and that it appears to be emerging as a
significant pathogen in immunocompromised individuals (our
present data and references 7, 8, 23, and 24), continued global
monitoring of this organism may be prudent.
In the countries participating in this study, the rates of sus-
ceptibility of C. albicans to fluconazole were similar. One ex-
ception was Australia, where only 90.5% of 21 isolates were
fluconazole susceptible (i.e., 2 resistant isolates) in 2001. The
2001 data from Australia are, however, from only one institu-
tion, and whether they reflect a sample bias, reference testing
from other institutions, or the general C. albicans population in
Australia requires further investigation.
Fluconazole is widely used to treat non-life-threatening and
life-threatening yeast infections and is used in some institu-
tions for prophylaxis in patient populations particularly suscep-
tible to the development of serious yeast infections. Increased
usage raises the concern that increased resistance to flucon-
azole in C. albicans, the most commonly isolated yeast, could
occur. In the present study, a decrease in the relative percent-
age of S C. albicans isolates occurred at three locations: gen-
eral medicine units, medical ICUs, and NICUs. This is based
on a lower overall rate of C. albicans isolation, because most C.
albicans infections were likely prevented by successful prophy-
laxis. Although, in general, a relatively higher proportion of
fluconazole-resistant isolates was obtained from respiratory
specimens, this specimen type was not more likely than others
to contain resistant isolates (Table 5). No specimen type was
associated with a disproportionately higher rate of resistant C.
albicans. In addition, there was no clear disproportionality in
specimen types containing fluconazole-resistant C. glabrata
(Table 8).
The two patient care locations with the highest rates of
fluconazole-resistant C. albicans were general medicine units
and other locations in 2001. However, the relative rate of
resistant organisms was not disproportionate to the relative
rate of C. albicans isolates from those units. The one unit with
a disproportionate rate of fluconazole-resistant C. albicans
(3%) was the NICU, with about 1% of the total C. albicans
isolates; the reason for this is unclear. Whether the few resis-
tant isolates from the NICU were from hospitals in which
fluconazole was used for prophylaxis is unknown. A similar
relatively higher rate was observed in 2000, although no resis-
tance was reported in 1997 to 1999. The NICU was also the
hospital location with the highest percentage of C. glabrata
isolates that were resistant, although the total number of C.
glabrata isolates was one-fourth of the total number of C.
albicans isolates. A recent study has shown that prophylactic
fluconazole therapy of very low birth weight (preterm) new-
borns during their first 6 weeks of life lowers the likelihood of
developing serious yeast infections (8). If this approach to
prophylaxis becomes a standard of care, these NICU infection
patterns should be carefully monitored.
Previous studies have demonstrated the utility of the auto-
mated image analysis plate reader system (BIOMIC) for as-
sessment of fluconazole and other disk susceptibilities (9, 12).
This automated system provides a reproducible electronic
means of assessing the in vitro susceptibility of yeast isolates.
The agar disk diffusion method used in this study uses a 0.5
McFarland turbidity inoculum standard and incubation at 35°C
for 18 to 24 h, as in bacterial testing. However, Mueller-Hinton
agar was supplemented with 2% glucose and 0.5 g of meth-
ylene blue per ml (1, 2, 9, 12). The NCCLS Antifungal Sub-
committee formally endorsed this new method in January
2003, but with an incubation time of 20 to 24 h. Publication of
document M44-P is scheduled for 2003. The QC results ob-
tained during 2001 support the reproducibility of this system
for fluconazole susceptibility testing. Unlike previous years of
the study, voriconazole, a recent FDA- and European Agency
for the Evaluation of Medical Products-approved triazole, was
also tested in 2001. QC results demonstrated good reproduc-
ibility with the C. albicans ATCC 90028 reference strain.
Greater variation was observed with C. parapsilosis ATCC
22019. Either the acceptable-performance range(s) will require
adjustment, or laboratories will need to learn to read the zones
more conservatively, i.e., as smaller.
The results of this study demonstrate that both voriconazole
and fluconazole exhibit potent in vitro activity against most
clinical yeast species. Voriconazole demonstrated markedly
enhanced activity, with 10- to 100-fold lower MICs, similar to
TABLE 9. Fluconazole and voriconazole agar disk gradient MICs
for C. albicansa
Country (no. of sites
in 2001)
Fluconazole Voriconazole
MIC50 MIC90 n MIC50 MIC90 n
Argentina (2) 0.32 1.84 607 0.019 0.128 471
Australia (1) 0.53 64.98 21 0.019 0.789 21
Belgium (2) 0.25 0.68 450 0.008 0.040 372
Brazil (1) 0.25 1.44 446 0.008 0.061 333
Canada (2) 0.41 1.12 87 0.019 0.085 87
China (2) 0.87 3.90 93 0.053 0.196 92
Colombia (2) 1.44 10.58 390 0.082 1.118 369
Czech Republic (2) 0.68 3.90 938 0.046 0.350 720
Ecuador (1) 2.37 42.11 250 0.096 4.80 174
France (4) 0.87 3.90 456 0.046 0.262 274
Germany (5) 0.25 1.12 299 0.014 0.061 299
Greece (1) 0.25 1.28 88 0.008 0.061 88
Hungary (5) 0.87 10.58 1,016 0.061 1.496 873
Italy (7) 0.68 5.00 696 0.030 0.262 696
Malaysia (1) 0.41 3.04 1,246 0.046 0.350 521
Mexico (2) 1.12 4.45 23 0.082 1.512 18
The Netherlands (1) 0.32 1.12 1,204 0.014 0.061 1,204
Poland (1) 0.41 1.12 170 0.046 0.146 45
Russia (1) 3.04 91.22 11 0.061 0.262 4
Slovakia (4) 0.87 5.00 391 0.046 0.977 391
South Africa (5) 0.41 2.37 1,049 0.019 0.109 1,010
South Korea (1) 0.53 1.84 426 0.026 0.146 347
Spain (2) 0.41 3.04 969 0.014 0.146 966
Switzerland (2) 0.41 1.84 161 0.019 0.082 161
Taiwan (3) 1.44 6.42 399 0.082 0.625 394
Thailand (2) 0.68 2.70 130 0.034 0.262 129
Turkey (2) 0.68 3.47 141 0.046 0.350 111
United Kingdom (3) 0.53 3.04 977 0.019 0.146 692
United States (9) 0.53 3.04 676 0.026 0.196 682
Venezuela (1) 1.44 5.00 120 0.071 0.350 98
a All specimen types were tested, all locations were in hospitals and only 2001
data are shown. Test range: fluconazole, 0.25 to 165 g/ml; voriconazole,
0.008 to 4.8 g/ml.
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the observations of others (18, 19). Voriconazole also appears
to be more active in vitro than fluconazole for several species
considered less susceptible to fluconazole (15), namely, C. kru-
sei, C. norvegensis, and C. inconspicua. Isolates of another flu-
conazole-resistant species, T. beigelii, exhibited similar rates of
susceptibility to voriconazole and fluconazole, with approxi-
mately 65% of the isolates testing S. In contrast, all isolates
that were members of the basidiomycetous yeast genus
Rhodotorula were relatively resistant to both voriconazole and
fluconazole. Voriconazole also appeared to be significantly
more active than fluconazole against C. rugosa and C. neofor-
mans. These results suggest that voriconazole may be effective
for treating infections caused by several species of yeasts con-
sidered inherently resistant to fluconazole. Despite the avail-
ability of only 1 year of voriconazole data, these results suggest
that fluconazole use has not led to the development or selec-
tion of azole-resistant species.
A recent study by Pfaller et al. (17) reported results from
susceptibility tests of a collection of selected sterile body site
yeast isolates from many of these same ARTEMIS study sites;
those isolates were tested by the NCCLS broth microdilution,
Etest, and NCCLS disk diffusion methods at one reference
laboratory. A comparison of the cumulative fluconazole and
voriconazole MICs reported in both studies by three methods
showed a high correlation. The few and relatively small differ-
ences may be attributed to the fact that the Pfaller study
reported on only isolates from sterile body sites, whereas this
study reports on isolates obtained from all body sites. A more
in-depth comparison of results from these two studies is in
progress.
The collection and annual analysis of quantitative well-con-
trolled in vitro susceptibility test data to assess trends and
patterns in antifungal activity helps to assess whether particu-
lar antifungal agents are becoming less useful for the treatment
of infections with specific yeast species. Our data demonstrate
that, on a global scale, fluconazole susceptibility among differ-
ent yeast species remained generally the same over the 4.5-year
study period and that voriconazole is indeed an extended-
spectrum triazole with increased in vitro activity versus Can-
dida species. Voriconazole may prove to be a valuable alter-
native agent for the treatment of infections with Candida spp.,
including several species considered to be less susceptible to
fluconazole.
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